论文部分内容阅读
神经内分泌肿瘤(neuroendocrine tumor,NET)是一类较罕见的上皮源性肿瘤,其细胞具有神经内分泌分化特征。近年来,NET总发病率呈明显上升趋势,其中胃肠胰腺神经内分泌肿瘤(gastroenteropancreatic neuroendocrine tumors,GEP-NETs)占NET总发病数的70%左右。胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumor,PNET)发病率较低,但由于肿瘤局部进展或远处转移而无法手术的患者预后不佳。分子靶向治疗药物舒尼替尼(sunitinib,SUTENT~(?))和依维莫司(everolimus,RAD001,AFINITOR~(?))为晚期高分化PNET提供了新的治疗选择。
Neuroendocrine tumor (NET) is a rare type of epithelial tumor with neuroendocrine differentiation. In recent years, the overall incidence of NET showed a clear upward trend, of which gastroenteropancreatic neuroendocrine tumors (GEP-NETs) accounted for about 70% of the total number of NET incidence. The incidence of pancreatic neuroendocrine tumor (PNET) is low, but patients with inoperable due to local tumor progression or distant metastasis have a poor prognosis. Molecular targeted therapies sunitinib (SUTENT ~ (?)) And everolimus (RAD001, AFINITOR ~ (?)) Provide a new therapeutic option for late well-differentiated PNET.